FDA DEVICE FACTS
Crux Vena Cava Filter System, femoral; Crux Vena Cava Filter System, jugular
Volcano Corporation
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The Crux Vena Cava Filter (VCF) System is indicated for the prevention of recurrent pulmonary embolism via placement in the inferior vena cava (IVC) in the following situations:
• pulmonary thromboembolism when anticoagulants are contraindicated;
• failure of anticoagulant therapy in thromboembolic disease;
• emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced;
• chronic, recurrent pulmonary embolism where anticoagulant therapy has failed or is contraindicated.
The Crux VCF may be removed according to the instructions contained in the section “Optional Retrieval of the Crux VCF” in patients who no longer require a vena cava filter. Retrieval of the filter can be performed by femoral or jugular approach.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。